Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

By L. Ostrosky-Zeichner, B. Alexander, D. Kett, J. Vázquez, P. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura and 2 more. Clinical Infectious Diseases, 2005

661 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/a4a3a712e61c89f3d7e7f0cee59527bcaa0210b9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. D. Kontoyiannis
2. T. Walsh
3. Thierry Calandra
4. E. Anaissie
5. M. Pfaller
6. D. Diekema

In Infectious Diseases

1. D. Kontoyiannis
2. J. Fishman
3. E. Anaissie
4. M. Pfaller
5. D. Diekema

Citations in the corpus

• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, methodology): “Aerosolized formulations of AmBmay be considered as prophylaxis in patients with prolonged neutropenia (patients receiving induction/reinduction therapy for acute leukemia and allogeneic HSCT recipients following conditioning or during treatment of graft-vs-host disease [GVHD]) and in lung transplan”
• Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. (2008, positive): “assay was sensitive and specific in early detection of 20 proven or probable invasive fungal infections, including candidiasis, fusariosis, trichosporonosis, and aspergillosis [66, 69].”
• Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, result): “Detection of b-D-glucan has shown good overall performance characteristics, with a sensitivity of 80%–90% in patients with candidemia [104, 105], confirming previous results obtained in patients with hematological malignancies [106].”